Introduction
Medical device registration in Brazil is the structured regulatory and operational function through which a business determines whether a product is regulated as a medical device, identifies the applicable ANVISA risk class and secures the correct notification or marketing authorization route required for lawful commercialization in Brazil.
In practical terms, Brazil combines risk-based product classification, a local holder structure, technical dossier requirements and specific pathways that differ materially between lower-risk and higher-risk devices.
The subject is commercially important because Brazil is one of the largest medtech markets in Latin America, while mistakes around class, local holder responsibility, GMP, certification requirements or clinical evidence can delay or block lawful market entry.
Home
└── Jurisdictions
└── Brazil
└── Medical Device Registration Brazil
Identity
- Object: Medical Device Registration
- Jurisdiction: Brazil
- Object ID: BR.MDR.001
- Reference: MAR-BR-MDR-001-A
Core Framework
- ANVISA-centered device regulation
- Four risk classes from I to IV
- Notification for Class I and II devices
- Marketing Authorization for Class III and IV devices
Operating Logic
- Local Brazilian holder structure is mandatory for foreign manufacturers
- Higher-risk devices trigger fuller dossier and GMP demands
- Some device groups require conformity assessment under INMETRO-linked rules
- Lifecycle compliance continues after initial authorization
Executive Summary
Medical device registration in Brazil is the professional regulatory and market-access function concerned with determining whether a product falls within the Brazilian medical-device framework, identifying its risk class and securing the correct ANVISA pathway for lawful commercialization.
Brazil uses a class-based authorization system managed by ANVISA. ANVISA explains that medical equipment is premarketing authorized in Brazil by two regimes: Notification for Risk Class I and II devices and Marketing Authorization for Risk Class III and IV devices.
The pathway is therefore driven by class. Lower-risk devices usually follow a lighter notification route, while higher-risk devices move through a fuller authorization route with stronger dossier and compliance expectations.
For foreign market-entry planning, the local Brazilian holder is central. ANVISA states that foreign companies cannot obtain marketing authorizations directly and must have partner companies legally constituted in Brazil that will be legally responsible for the imported and distributed products.
| Definition | The professional regulatory and market-access function concerned with securing the lawful Brazilian notification or marketing authorization position for medical devices through classification, holder structure, dossier planning and lifecycle compliance. |
| Object | Medical Device Registration |
| Object Type | Professional Regulatory and Market-Access Function |
| Classification | Medical Devices, Brazil, ANVISA, Notification, Marketing Authorization, Risk Class I, Risk Class II, Risk Class III, Risk Class IV, Holder, GMP |
| Jurisdiction | Brazil |
Definition
Medical device registration in Brazil refers to the structured process through which a business determines whether its product is regulated as a medical device in Brazil, identifies its risk class and secures the appropriate notification or marketing authorization route before commercialization.
The object is broader than filing an application. It covers device qualification, class mapping, holder structure, technical documentation, conformity assessment, GMP readiness, clinical evidence strategy where needed and post-market maintenance.
| Covered Matters | Device qualification, class determination, notification versus marketing authorization analysis, Brazilian holder structure, technical dossier planning, conformity assessment, GMP readiness, labeling, clinical evidence and maintenance. |
| Functional Boundary | The Registry Object covers how businesses achieve and maintain lawful Brazilian market access for medical devices. |
| Related but Not Primary | Public procurement, reimbursement, distribution contracting, patent strategy and broader healthcare commercialization are adjacent but not the primary object here. |
| Outside Scope | Pharmaceutical-only approvals, unrelated consumer-product regulation, general company formation and broad tax planning. |
Scope
The Brazilian medical device registration function applies to products regulated as medical devices under ANVISA’s framework and to the companies responsible for lawfully placing those products on the Brazilian market.
The scope is both product-facing and structure-facing. ANVISA not only defines what a medical device is under RDC No. 751/2022, but also places responsibility on an ANVISA-regularized applicant company and recognizes a legally responsible holder for supply in Brazil.
Editorial Note: In Brazil, a registration review is incomplete if it looks only at the product and ignores the Brazilian partner or holder that will legally maintain the authorization.
Purpose
The purpose of medical device registration in Brazil is to convert a product, technical file and commercialization plan into a lawful ANVISA market-entry position.
In business terms, the function exists to identify the correct class-based route, structure the Brazilian holder model, determine whether notification or marketing authorization applies and reduce the risk of entering Brazil on an unsupported regulatory assumption.
Primary Outcome
A coherent Brazilian medical device registration position means that the device has been qualified correctly, mapped to the appropriate risk class and linked to the correct ANVISA route for lawful commercialization.
Depending on class, the outcome may be a notification for a Class I or II device or a marketing authorization for a Class III or IV device. ANVISA explains that notification for lower-risk devices does not expire, while marketing authorizations for higher-risk devices are valid for ten years and may be renewed for equal and successive periods.
Request Contexts
Request contexts show the business situations in which Brazilian registration work is usually activated. Most begin before launch, but the function is also relevant in holder changes, product modifications and renewal planning.
| Identity Pattern | Manufacturer planning Brazilian entry, foreign manufacturer evaluating holder options, regulatory lead reviewing ANVISA classification, local partner assessing GMP obligations, investor validating device regularization architecture. |
| Business Event | First Brazilian launch, class uncertainty, notification versus authorization analysis, conformity assessment planning, GMP planning, clinical evidence strategy, renewal or authorization maintenance. |
| Typical User | Manufacturers, Brazilian holders, local distributors, regulatory affairs managers, legal advisers, investors and international medtech businesses. |
| Typical Scenario | A company needs to determine whether its product falls into the Brazilian notification or marketing authorization route, who will legally hold the authorization in Brazil and what documentation, GMP and certification obligations apply. |
Typical Users
Different actors encounter Brazilian registration from different positions, but the common issue is the need for a defensible answer on class, route and Brazilian legal-holder structure.
| Foreign Manufacturer | Needs to determine class, route, Brazilian holder structure and whether the product triggers conformity assessment, GMP or clinical evidence work. |
| Brazilian Holder | Needs to maintain the authorization and act as the legally responsible supplier of the device in Brazil. |
| Regulatory Affairs Lead | Needs to align class, technical documentation, labeling, GMP and route strategy with ANVISA requirements. |
| Quality or Operations Lead | Needs to ensure manufacturing sites and quality systems can support Brazilian regulatory expectations, particularly for higher-risk devices. |
| Commercial Team | Needs to understand whether the product can launch under notification or must wait for full marketing authorization. |
Typical Scenarios
Practical scenarios show where Brazilian registration analysis becomes operationally important.
| Initial Qualification | The business must determine whether the product is regulated as a medical device in Brazil under RDC No. 751/2022. |
| Class Strategy | The company needs to determine whether the device falls into Class I, II, III or IV, because that drives the market-entry route. |
| Notification Route | The manufacturer needs to assess whether a Class I or II notification route is available and sufficient. |
| Marketing Authorization Route | The business needs to prepare for the fuller ANVISA authorization route applicable to Class III or IV devices. |
| Conformity Assessment | The company needs to determine whether the product type requires certification under the Brazilian Conformity Assessment System before ANVISA filing. |
| Clinical Evidence Review | The business needs to determine whether clinical evidence is necessary, especially for higher-risk devices. |
Jurisdiction Characteristics
Brazil is an ANVISA-centered medical-device jurisdiction with strong reliance on formal risk classes, local legal responsibility and differentiated routes for lower-risk and higher-risk products.
A distinctive practical feature is that foreign companies do not obtain authorizations directly. ANVISA states that foreign companies must work through partner companies legally constituted in Brazil that will be legally responsible for the products imported into and distributed within the country.
| Operational Culture | Formal, class-based and strongly tied to the Brazilian legal holder responsible for the device. |
| Legal Framework Orientation | ANVISA-led authorization system built around notification, marketing authorization, GMP and sector-specific technical rules. |
| Commercial Context | Large strategic market in Latin America where compliant local structure and route planning are decisive. |
| Language Expectation | Portuguese-language regulatory practice and dossier handling are central in real-world market entry. |
Key Authorities
Brazilian medical device registration is centered on the Agência Nacional de Vigilância Sanitária. ANVISA describes itself as the Brazilian Health Regulatory Agency responsible for sanitary control of products and services subject to health regulation throughout the national territory.
| Official Name | Agência Nacional de Vigilância Sanitária |
| Official English Name | Brazilian Health Regulatory Agency (ANVISA) |
| Primary Role | National authority responsible for regulating, authorizing and supervising medical devices in Brazil. |
| Responsibilities | Defines classification and authorization pathways, oversees notification and marketing authorization, supervises GMP-related requirements and manages health-regulatory control for products marketed in Brazil. |
| Typical Interaction | Direct where a business needs classification strategy, notification or authorization analysis, conformity assessment planning, GMP alignment or lifecycle maintenance. |
| Official Website | ANVISA Medical Devices |
| Cross-Border Relevance | High, because foreign manufacturers must structure entry through Brazilian partners or holders recognized under the ANVISA framework. |
Applicable Legislation
The Brazilian framework combines general medical-device rules with more detailed requirements for classification, authorization, GMP, software, conformity assessment and lifecycle safety. ANVISA’s official medical-devices page identifies RDC No. 751/2022 as the core resolution defining medical devices and the notification and marketing authorization regimes.
| Official Title | Collegiate Board Resolution RDC No. 751/2022 |
| Year | 2022 |
| Purpose | Defines what a medical device is, establishes risk classification rules and governs notification and marketing authorization regimes. |
| Typical Application | Used to determine whether a device follows Notification or Marketing Authorization and how the product should be classified from Risk Class I to IV. |
| Related Legislation | RDC No. 848/2024, RDC No. 549/2021, RDC No. 657/2022, RDC No. 579/2021 and additional product-specific rules. |
| Official Source | ANVISA Medical Devices |
| Current Status | Active framework. |
| Official Title | Collegiate Board Resolution RDC No. 848/2024 |
| Year | 2024 |
| Purpose | Defines essential safety and performance requirements to be maintained throughout the life cycle of a device. |
| Typical Application | Used to support safety and performance compliance from conception to decommissioning. |
| Related Legislation | RDC No. 751/2022 and other technical device rules. |
| Official Source | ANVISA Medical Devices |
| Current Status | Active framework. |
Process Flow
Brazilian medical device registration normally works as a staged process from product qualification to commercialization. ANVISA’s official framework starts with device definition and risk classification and then connects the product to either Notification or Marketing Authorization depending on class.
| 1. Product Qualification | Determine whether the product is regulated as a medical device in Brazil. |
| 2. Risk Classification | Identify the applicable Risk Class I, II, III or IV. |
| 3. Holder Structure | Appoint or align the Brazilian company that will be legally responsible for supply and authorization maintenance. |
| 4. Conformity Assessment Review | Determine whether the device requires certification within the Brazilian Conformity Assessment System before ANVISA application. |
| 5. GMP and Quality Readiness | For higher-risk routes, ensure that the manufacturing unit can support ANVISA GMP expectations. |
| 6. Dossier Preparation | Prepare the technical documentation, labeling, representative authorizations and supporting evidence needed for the route. |
| 7. Notification or Marketing Authorization | Proceed with the applicable ANVISA pathway according to class. |
| 8. Market Launch | Commercialize the device after the relevant Brazilian authorization position is in place. |
| 9. Post-Market Maintenance | Maintain renewals, changes, safety obligations and holder compliance after launch. |
| Typical Outputs | Qualification memo, class rationale, holder structure file, conformity assessment records, technical dossier, GMP support file and maintenance file. |
Decision Tree
The decision tree helps simplify the main Brazilian threshold questions.
- Confirm whether the product is regulated as a medical device in Brazil.
- Determine the risk class because Brazil uses four classes from I to IV.
- Establish which Brazilian company will legally hold the authorization and supply the product in Brazil.
- If the product is Class I or II, determine whether the Notification route is the correct pathway.
- If the product is Class III or IV, prepare for the Marketing Authorization route and fuller dossier review.
- Assess whether conformity assessment, INMETRO-related certification or other sector-specific requirements apply before filing.
- Assess whether GMP certification, clinical evidence or other higher-risk supporting materials are required.
- Commercialize only after the correct Brazilian legal position is secured.
Timeline
The Brazilian timeline begins before launch and continues after commercialization. The exact route depends on risk class, technical category, conformity assessment requirements and whether the product falls into a higher-control route.
| Concept Stage | The business defines the product, intended use and Brazilian market objective. |
| Qualification Stage | The product is assessed to determine whether it is a medical device under Brazilian rules. |
| Classification Stage | The risk class is mapped because it determines the authorization route. |
| Structure Stage | The Brazilian holder or partner company is identified and formalized. |
| Readiness Stage | Conformity assessment, GMP and evidence requirements are reviewed where relevant. |
| Submission Stage | The business proceeds with Notification or Marketing Authorization according to class. |
| Launch Stage | The device is commercialized after the applicable Brazilian authorization position is complete. |
| Maintenance Stage | The business and holder manage renewals, changes and continuing compliance obligations. |
Required Documents
The exact document set depends on class and pathway, but Brazilian medical device registration depends on a coherent documentary file that supports classification, holder structure and compliance readiness.
| Document | Product Qualification and Classification Record |
| Purpose | Explains why the product is regulated as a medical device in Brazil and what risk class applies. |
| Typical Situation | Prepared at the beginning of Brazilian registration strategy. |
| Document | Holder and Authorization Structure File |
| Purpose | Documents the Brazilian company that will act as the legally responsible holder for the authorization. |
| Typical Situation | Used whenever a foreign manufacturer plans Brazilian market entry. |
| Document | Technical Dossier |
| Purpose | Supports notification or marketing authorization with labeling, images, device information and other technical data. |
| Typical Situation | Used in both lower-risk and higher-risk routes, with greater depth for higher-risk products. |
| Document | Conformity Assessment or Certification File |
| Purpose | Supports device categories that require certification under the Brazilian Conformity Assessment System. |
| Typical Situation | Used for electromedical equipment and other specifically regulated products. |
| Document | GMP and Quality Compliance File |
| Purpose | Supports higher-risk routes where ANVISA GMP certification or related evidence is required. |
| Typical Situation | Used particularly for Class III and IV routes. |
Cross-Border Relevance
Cross-border relevance is high because many non-Brazilian manufacturers rely on Brazilian partner companies to place products on the market. ANVISA states that foreign companies cannot obtain marketing authorizations directly and must use companies legally constituted in Brazil that will be legally responsible for the products.
The cross-border issue is therefore not simply whether the device is approved elsewhere. It is whether the manufacturer has mapped the Brazilian class, holder model, route and supporting certification or GMP obligations required by ANVISA.
| Recognition | Brazilian market access depends on ANVISA compliance rather than automatic recognition of foreign approvals. |
| Foreign Companies | Foreign manufacturers must structure entry through Brazilian partner companies or holders. |
| Language Considerations | Portuguese-language regulatory materials and local dossier practice are central in real market access work. |
| International Rules | Cross-border businesses must treat holder structure, conformity assessment and GMP readiness as core workstreams. |
| Practical Considerations | Brazilian entry strategy should treat class, route, local holder and manufacturing-system readiness as one integrated architecture. |
| Typical Risk | Assuming a foreign manufacturer can control Brazilian market entry directly without a properly structured local holder or without adapting the route to ANVISA’s class logic. |
ANVISANotificationMarketing AuthorizationRisk Classes I-IVHolderGMP
Operating Constraints & Risks
Operating constraints identify the recurring failure points in Brazilian medical device registration. Many arise when businesses underestimate how important local-holder structure and class-based route selection are.
| Qualification Risk | The product is misread as a medical device or non-device under Brazilian rules. |
| Class Risk | The wrong risk class is assumed, leading to the wrong route between Notification and Marketing Authorization. |
| Holder Risk | The Brazilian legal-holder structure is not set up correctly before filing or commercialization. |
| Certification Risk | Sector-specific conformity assessment is overlooked for products that require certification before ANVISA application. |
| GMP Risk | The business underestimates GMP expectations for higher-risk devices or assumes authorization can be completed without manufacturing readiness. |
| Clinical Evidence Risk | Higher-risk products are advanced without a defensible clinical evidence strategy where such support may be expected. |
| Maintenance Risk | Renewals, changes and continuing compliance are not managed after launch. |
Costs & Fees
Brazilian medical device registration costs arise from several separate components rather than one single filing step. Class strategy, holder structure, certification, GMP and technical documentation can all affect the cost profile.
| Assessment Costs | Classification analysis, route planning and Brazilian regulatory strategy can be substantial depending on device complexity. |
| Holder Costs | The Brazilian holder model often creates ongoing commercial and compliance cost because it is central to market access. |
| Certification Costs | Products requiring conformity assessment and certification under Brazilian systems can generate meaningful direct and indirect project cost. |
| GMP Costs | Higher-risk routes may create significant cost through audit preparation, GMP support and manufacturing compliance work. |
| Dossier Costs | Preparing the technical file, labeling and supporting evidence can be substantial, especially for Class III and IV devices. |
| Maintenance Costs | Renewals, changes and ongoing holder obligations create continuing expense after launch. |
FAQ
The FAQ section addresses recurring threshold questions in Brazilian market-entry work.
| Who Regulates Medical Devices in Brazil? | Medical devices in Brazil are regulated by ANVISA, the Brazilian Health Regulatory Agency. |
| How Many Device Classes Does Brazil Use? | Brazil uses four risk classes, from Class I to Class IV. |
| What Is the Difference Between Notification and Marketing Authorization? | ANVISA states that Notification applies to Risk Class I and II devices, while Marketing Authorization applies to Risk Class III and IV devices. |
| Can a Foreign Manufacturer Apply Directly to ANVISA? | No. ANVISA states that foreign companies cannot obtain administrative authorizations directly and must work through companies legally constituted in Brazil. |
| Do Higher-Risk Devices Have Expiry? | Yes. Marketing authorizations for Class III and IV devices are valid for ten years and may be renewed. |
| Do Lower-Risk Devices Expire? | No. ANVISA states that Notification for Class I and II devices does not expire, though it may be cancelled in certain circumstances. |
Practical Guidance
Practical guidance helps a business prepare before finalising a Brazilian market-entry strategy.
| Checklist | What exactly is the product under Brazilian law? What risk class applies? Is the route Notification or Marketing Authorization? Which Brazilian company will legally hold the authorization? Does the product require conformity assessment or certification before ANVISA filing? Does the route require GMP support or manufacturing-site readiness? Is clinical evidence needed for the device category? Has the technical dossier and labeling package been prepared for the correct route? Are renewal, change-control and post-market responsibilities clearly allocated? |
A disciplined Brazilian registration review should start with class and holder structure. In many failed launches, the visible filing problem is only a later symptom of an earlier error about who legally holds the route in Brazil, what class the device belongs to or whether the product needed a more demanding authorization path than originally assumed.
Jurisdictional Expert
The Jurisdictional Expert section records the status of the registry position associated with this jurisdictional object. It remains separate from the editorial content.
| Registry Position ID | RE-BR-MDR-001 |
| Registry Position | Jurisdictional Expert Medical Device Registration Brazil |
| Registry Availability | Open |
| Verification Status | No verified participant currently assigned to this registry position. |
| Coverage | Brazil medical device registration with emphasis on ANVISA class logic, notification and marketing authorization routes, Brazilian holder structure, conformity assessment and GMP readiness. |
| Registry Reference | MAR-BR-MDR-001-A Jurisdictional Expert Position |
| Contact Information | Registry position not yet assigned. |
Machine Layer
This section contains machine-oriented registry fields retained for indexing, retrieval, system organisation and future rendering control. It may be visually minimised while remaining fully available in the HTML source.
| Object DNA | medical device registration brazil anvisa notification marketing authorization risk class i class ii class iii class iv holder gmp conformity assessment clinical evidence market access |
| AI Retrieval Summary | Neutral registry object describing how medical device registration operates in Brazil, including ANVISA-centered class logic, notification and marketing authorization routes, Brazilian holder requirements, conformity assessment, GMP readiness and lifecycle maintenance. |
| Entity Index | Brazil Medical Device Registration ANVISA Notification Marketing Authorization Holder GMP Risk Classes I II III IV |
| Machine Metadata | Registry rendering layer https://market-access-records.org/css/registry.css | Object ID BR.MDR.001 | Machine Reference MAR-BR-MDR-001-A | Internal Classification Business > Regulatory & Market Access > Medical Device Registration > Brazil | Checksum 0xMDR66BR |
| Internal References | Registry Object | Jurisdiction Node | Editorial Record | Jurisdictional Expert Position | Machine-readable Reference Node |